tetano
Editor, Senior Moderator
Vaccine
. 2026 Feb 5:76:128312.
doi: 10.1016/j.vaccine.2026.128312. Online ahead of print.
Use cases for pan-sarbecovirus vaccines: a workshop report
Emily A Smith[SUP] 1 [/SUP], Melissa Malhame[SUP] 2 [/SUP], Stefano Malvolti[SUP] 2 [/SUP], Gerald Voss[SUP] 3 [/SUP], Saket Thaker[SUP] 3 [/SUP], Angela K Ulrich[SUP] 4 [/SUP], Julia T Ostrowsky[SUP] 4 [/SUP], Derek F Fleming[SUP] 4 [/SUP], Nadia Cohen[SUP] 3 [/SUP], Michael T Osterholm[SUP] 4 [/SUP], Eve M Lackritz[SUP] 4 [/SUP]
Affiliations
Following the emergence of SARS-CoV-2, a global consensus arose on the need for a vaccine capable of protecting the human population from both known and unknown coronavirus threats. In April 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Center for Infectious Disease Research and Policy (CIDRAP) hosted a workshop to establish use cases for broadly protective coronavirus vaccines, using a pan-sarbecovirus vaccine candidate for prevention of SARS-CoV-X as an example. Workshop participants discussed implementation strategies and ideal product characteristics of pan-sarbecovirus vaccines that could be readily deployed within 100 days of SARS-CoV-X emergence. Here, we summarize the outputs from the workshop, which include the established use cases, as well as key considerations for research and development of pan-sarbecovirus vaccine candidates with characteristics to meet global needs. These use cases will be used to guide future investments and advance pandemic preparedness in line with CEPI's mission to develop safe, effective, globally accessible vaccines in as little as 100 days.
Keywords: Coronavirus; betacoronavirus; pandemic; sarbecovirus; vaccine.
. 2026 Feb 5:76:128312.
doi: 10.1016/j.vaccine.2026.128312. Online ahead of print.
Use cases for pan-sarbecovirus vaccines: a workshop report
Emily A Smith[SUP] 1 [/SUP], Melissa Malhame[SUP] 2 [/SUP], Stefano Malvolti[SUP] 2 [/SUP], Gerald Voss[SUP] 3 [/SUP], Saket Thaker[SUP] 3 [/SUP], Angela K Ulrich[SUP] 4 [/SUP], Julia T Ostrowsky[SUP] 4 [/SUP], Derek F Fleming[SUP] 4 [/SUP], Nadia Cohen[SUP] 3 [/SUP], Michael T Osterholm[SUP] 4 [/SUP], Eve M Lackritz[SUP] 4 [/SUP]
Affiliations
- PMID: 41650672
- DOI: 10.1016/j.vaccine.2026.128312
Following the emergence of SARS-CoV-2, a global consensus arose on the need for a vaccine capable of protecting the human population from both known and unknown coronavirus threats. In April 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Center for Infectious Disease Research and Policy (CIDRAP) hosted a workshop to establish use cases for broadly protective coronavirus vaccines, using a pan-sarbecovirus vaccine candidate for prevention of SARS-CoV-X as an example. Workshop participants discussed implementation strategies and ideal product characteristics of pan-sarbecovirus vaccines that could be readily deployed within 100 days of SARS-CoV-X emergence. Here, we summarize the outputs from the workshop, which include the established use cases, as well as key considerations for research and development of pan-sarbecovirus vaccine candidates with characteristics to meet global needs. These use cases will be used to guide future investments and advance pandemic preparedness in line with CEPI's mission to develop safe, effective, globally accessible vaccines in as little as 100 days.
Keywords: Coronavirus; betacoronavirus; pandemic; sarbecovirus; vaccine.